Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

27.3%

3 terminated/withdrawn out of 11 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

10(90.9%)

Phase 3

1(9.1%)

11Total

Phase 1(10)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT05377996Phase 1Recruiting

A Study of XMT-1660 in Participants With Solid Tumors

Role: lead

NCT05514717Phase 1Recruiting

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Role: lead

NCT06517485Phase 1Completed

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

Role: lead

NCT06517433Phase 1Completed

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Role: lead

NCT04396340Phase 1Terminated

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Role: lead

NCT03319628Phase 1Active Not Recruiting

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Role: lead

NCT05329545Phase 3Terminated

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

Role: lead

NCT04907968Phase 1Terminated

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Role: lead

NCT02952729Phase 1Completed

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

Role: lead

NCT01011972Phase 1Completed

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors

Role: lead

NCT00455052Phase 1Completed

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Role: lead

All 11 trials loaded